Clinical trial
Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
NCT03784599 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- Lead sponsor
- The Netherlands Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 18, 2018
- Completion date
- May 17, 2021
- Enrollment
- 28 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.